PROFILE |
 |
We've mapped the human genome -- now what? CombiMatrix is developing technology to make customizable biological arrays for biotech and pharmaceutical firms and academic research labs to analyze the glut of genetic information now available. Used to identify the roles of genes and proteins, the arrays feature the firm's software, which synthesizes or immobilizes DNA, RNA, peptide, or small molecule sequences, and "virtual flask" technology that prevents cross-contamination. In addition to gene variation and gene function detection systems, it is also working on proteomic devices to detect gene expression at the protein level. Acacia Research, which provided seed funding for CombiMatrix, owns a majority stake in it.
COMPETITION |
 |
Affymetrix, Inc. (AFFX)
Hyseq, Inc. (HYSQ)
Incyte Genomics, Inc. (INCY)
|
 |
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 0.00
1-Yr. Sales Growth: (88.1)%
Employees: 76
Revenue per employee: $0.00
KEY PEOPLE |
 |
Gerald D. Knudson
CEO
Stephen G. Burke
CFO
CONTACT INFO |
 |
6500 Harbour Pointe Pkwy, Ste. 301
Mukilteo, WA 98275
US
Phone: 425-493-2000
Fax: 425-493-2010
Online: Web Site
|